{"id":"incobotulinumtoxina-75-units","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site pain or bruising"},{"rate":"5-15","effect":"Headache"},{"rate":"1-5","effect":"Muscle weakness or paralysis (off-target)"},{"rate":"1-3","effect":"Eyelid ptosis"},{"rate":"1-2","effect":"Dry mouth"},{"rate":"5-10","effect":"Neck pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IncobotulinumtoxinA is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in temporary paralysis of injected muscles. The effect is localized to the injection site and gradually reverses over 3-4 months as new nerve terminals form.","oneSentence":"IncobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:53.296Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cervical dystonia"},{"name":"Blepharospasm"},{"name":"Hemifacial spasm"},{"name":"Glabellar lines (dynamic wrinkles)"},{"name":"Crow's feet"},{"name":"Forehead lines"}]},"trialDetails":[{"nctId":"NCT04826900","phase":"NA","title":"Wearable Robotic System and Robotic Mirror Therapy in Spastic Hemiplegia Post Botulinum Toxin Injection","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-08-01","conditions":"Hemiplegia, Spastic, Spastic","enrollment":31},{"nctId":"NCT02002884","phase":"PHASE3","title":"Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2014-03-28","conditions":"Cerebral Palsy, Spasticity","enrollment":351},{"nctId":"NCT02091739","phase":"PHASE3","title":"Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2014-04","conditions":"Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke","enrollment":184}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xeomin","NT 201","Botulinum toxin type A (150 kiloDalton), free from complexing proteins"],"phase":"phase_3","status":"active","brandName":"IncobotulinumtoxinA (75 Units)","genericName":"IncobotulinumtoxinA (75 Units)","companyName":"Merz Pharmaceuticals GmbH","companyId":"merz-pharmaceuticals-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IncobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}